Skip to content

Sudden, severe headache? Call 911 (US)

HeadacheCare

Migraine patch works in late-stage study

David Alexander M.D.Published August 12, 20092 min read

Key points

  • An experimental skin patch that delivers the powerful migraine drug sumatriptan through the skin eased migraine symptoms in a late-stage study, offering a potential new way to treat migraine without taking pills, the specialty drugmaker NuPathe Inc., reported on Tuesday.
  • Conshohocken, Pennsylvania-based NuPathe said in a statement that the patch showed a “statistically significant” improvement after two hours in pain, nausea, and sensitivity to light and sound compared to people who used a placebo.
  • Mark Pierce, chief scientific officer of the company, said the finding brings the company a step closer to being the first migraine patch on the market.
  • The results follow a dramatic showing in late May by MAP Pharmaceuticals Inc, whose inhaled migraine drug reached all four goals of a late stage clinical trial, sending shares up 150 percent.

An experimental skin patch that delivers the powerful migraine drug sumatriptan through the skin eased migraine symptoms in a late-stage study, offering a potential new way to treat migraine without taking pills, the specialty drugmaker NuPathe Inc., reported on Tuesday.

The patch, known as Zelrix, is designed to bring relief to people whose migraines are accompanied by nausea, which occurs in some 55 percent of migraine sufferers.

Conshohocken, Pennsylvania-based NuPathe said in a statement that the patch showed a “statistically significant” improvement after two hours in pain, nausea, and sensitivity to light and sound compared to people who used a placebo.

The trial included 530 patients. The most common side effects were itching, pain and tingling on the skin where the patch was applied. Most of these were mild and passed quickly.

Dr. Mark Pierce, chief scientific officer of the company, said the finding brings the company a step closer to being the first migraine patch on the market. NuPathe plans to apply for U.S. marketing approval in 2010.

Full results of the study will be released during the International Headache Society meeting in Philadelphia this September.

The results follow a dramatic showing in late May by MAP Pharmaceuticals Inc, whose inhaled migraine drug reached all four goals of a late stage clinical trial, sending shares up 150 percent.

That drug, known as Levadex, brought relief within 30 minutes and lasted 48 hours in a 792-patient trial.

Nearly 30 million Americans have migraines, an extremely painful, often throbbing type of headache, according to the National Headache Foundation.

CHICAGO (Reuters)

Written by

David Alexander M.D.

Last updated

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. A sudden, severe headache, or one with weakness, confusion, fever or a stiff neck, needs emergency care: call 911 (US) or your local emergency number.

When a headache is an emergency

Know the warning signs.

Most headaches are not dangerous, but some need care right away. If you or someone near you has any of these, call 911 (US) or your local emergency number.